Publication
Response of head and neck squamous cell carcinoma cells carrying PIK3CA mutations to selected targeted therapies.
Authors not recorded
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
Linked entities
Linked entities (11)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 11
- cancerMalignant Head and Neck Neoplasmcivic_curation1.00
- cancerMalignant Neoplasmcivic_curation1.00
- drugDactolisibcivic_curation1.00
- drugPictilisibcivic_curation1.00
- drugTanespimycincivic_curation1.00
- drugTrametinibcivic_curation1.00
- genePIK3CAcivic_curation1.00
- genePTENcivic_curation1.00
- variantPIK3CA H1047Rcivic_curation1.00
- variantPIK3CA Mutationcivic_curation1.00
- variantPTEN Mutationcivic_curation1.00
Curated evidence
Evidence citing this paper (4)
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 25855885
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| PIK3CA H1047R1 | ||||||||
| Dactolisib | Malignant Head and Neck NeoplasmALIAS | Predictive | D | Supports Sensitivity Response | 1 | accepted | EID1361Lentiviral transduction of PIK3CA H1047R mutation into head and neck cancer cell line SCC25 led to increased sensitivity to PI3K/mTOR inhibition with BEZ235 compared to unmanipulated cells (IC50 value… (full text at CIViC) PMID 25855885 · Wirtz et al., 2015 · Open in CIViC | civic |
| PIK3CA Mutation2 | ||||||||
| Pictilisib + Tanespimycin + TrametinibSubstitutes | Malignant Head and Neck NeoplasmALIAS | Predictive | D | Does Not Support Sensitivity Response | 2 | accepted | EID13646 head and neck cancer cell lines were tested for Response to 17-AAG, GDC-0941. Two of the cell lines did not carry PIK3CA mutations. No clear difference was shown between PIK3CA-mutant and wild-type … (full text at CIViC) PMID 25855885 · Wirtz et al., 2015 · Open in CIViC | civic |
| Pictilisib + TanespimycinSubstitutes | Malignant NeoplasmALIAS | Predictive | D | Does Not Support Sensitivity Response | 2 | accepted | EID1358Analysis of drug response data from the Sanger center cell line screen. Cell lines with either PI3K and/or PTEN mutations did not show a significant difference in response to class I PI3K inhibitor GD… (full text at CIViC) PMID 25855885 · Wirtz et al., 2015 · Open in CIViC | civic |
| PTEN Mutation1 | ||||||||
| Pictilisib + TanespimycinSubstitutes | Malignant Head and Neck NeoplasmALIAS | Predictive | D | Does Not Support Sensitivity Response | 2 | accepted | EID1359Analysis of drug response data from the Sanger center cell line screen. Cell lines with either PI3K and/or PTEN mutations did not show a significant difference in response to the class I PI3K inhibito… (full text at CIViC) PMID 25855885 · Wirtz et al., 2015 · Open in CIViC | civic |